NASDAQ$PGNY
Progyny Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Progyny, Inc. reported strong fourth quarter and full year 2024 financial results, with revenue growth and record Adjusted EBITDA, while also providing financial guidance for 2025.
Progyny, Inc. announced robust financial results for the fourth quarter of 2024, with revenue reaching $298.4 million, a 10.6% increase year-over-year. The company achieved a net income of $10.5 million and Adjusted EBITDA of $47.5 million, reflecting strong operational performance. Full year 2024 revenue increased by 7.2% to $1,167.2 million, with record Adjusted EBITDA of $198.8 million.
- Fourth quarter 2024 revenue increased by 10.6% to $298.4 million compared to $269.9 million in Q4 2023.
- Net income for Q4 2024 was $10.5 million, or $0.12 per diluted share, compared to $13.5 million, or $0.13 per diluted share in Q4 2023.
- Adjusted EBITDA for Q4 2024 grew by 10% to $47.5 million, with an Adjusted EBITDA margin of 15.9%.
- The company ended 2024 with 473 clients, an increase from 392 clients in 2023, and purchased 3,248,298 shares for $52.5 million through its share repurchase programs in Q4 2024.
Headline financials
Revenue & EPS history
Progyny · Revenue · Quarterly
$298M
Revenue by segment
Progyny · $281M total across 2 segments · Q3 2023
- Fertility Benefit Services$175M+35.4%62.3%
- Pharmacy Benefit Services$106M+39.0%37.7%
Forward guidance
Progyny provides financial guidance for the full year 2025 and the first quarter of 2025, anticipating continued revenue growth and strong Adjusted EBITDA, while acknowledging potential variability in member engagement.
Tailwinds
- Full year 2025 revenue is projected to be $1.175 billion to $1.225 billion, reflecting growth of 1% to 5%.
- First quarter 2025 revenue is projected to be $300.0 million to $318.0 million, reflecting growth of 8% to 14%.
- Adjusted EBITDA for full year 2025 is projected to be $188.0 million to $201.0 million.
- Adjusted earnings per diluted share for full year 2025 is projected to be $1.52 to $1.62.
- The company anticipates having more than 530 clients in 2025, representing an estimated 6.7 million covered lives.
Headwinds
- Net income for full year 2025 is projected to be $45.0 million to $53.9 million, a potential decrease from 2024.
- Net income per diluted share for full year 2025 is projected to be $0.49 to $0.59, a potential decrease from 2024.
- The guidance ranges reflect the possibility of further variability in member engagement in 2025, similar to unexpected variability experienced in 2024.
- A large client did not renew its services agreement for 2025, impacting revenue contribution.
- The lower net income in Q4 2024 was primarily due to a higher provision for income taxes driven by discrete tax impacts of equity compensation.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-1.1%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-0.2%
Avg return
30 days after
38%
11 / 29 earnings
Positive
+26.4%
Q2 2022
Best reaction
-20.5%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | +25.4% | +38.2% | |
| Q4 2025 | -20.5% | -20.0% | -22.4% | |
| Q3 2025 | +24.3% | +33.6% | +33.4% | |
| Q1 2025 | -9.7% | -6.5% | -7.2% | |
| Q4 2024 | -1.5% | -5.2% | -4.3% | |
| Q3 2024 | -18.5% | -19.3% | -12.9% | |
| Q2 2024 | -17.7% | -14.7% | -6.4% | |
| Q1 2024 | -14.4% | -14.6% | -14.2% | |
| Q4 2023 | -13.1% | -9.7% | -4.3% | |
| Q3 2023 | -4.3% | -2.1% | +17.8% | |
| Q2 2023 | +4.9% | -2.8% | -8.6% | |
| Q1 2023 | +9.3% | +5.9% | +16.8% | |
| Q4 2022 | +22.9% | +18.4% | +7.7% | |
| Q3 2022 | -2.6% | +2.0% | -13.8% | |
| Q2 2022 | +26.4% | +25.5% | +15.4% | |
| Q1 2022 | -7.1% | -15.6% | -23.1% | |
| Q4 2021 | +11.5% | +13.0% | +31.6% | |
| Q3 2021 | +2.5% | +5.8% | -22.2% | |
| Q2 2021 | -12.8% | -17.1% | +4.3% | |
| Q1 2021 | -3.2% | -8.7% | +18.4% | |
| Q4 2020 | -15.5% | -14.9% | -14.4% | |
| Q3 2020 | -0.3% | +7.0% | +38.7% | |
| Q2 2020 | +0.4% | +8.4% | -0.9% | |
| Q1 2019 | -2.4% | +4.8% | -13.7% | |
| Q1 2020 | +21.8% | +18.8% | +2.1% | |
| Q4 2017 | -3.7% | -6.3% | -8.3% | |
| Q4 2019 | -12.2% | -15.5% | -39.0% | |
| Q4 2018 | -0.2% | -5.0% | -7.0% | |
| Q3 2019 | +0.5% | +0.3% | -6.5% | |
| Q2 2019 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro